⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27976 | 0.82 | MGAM (0.61) | — | |
| SCHEMBL436686 | 0.79 | — | — | |
| SCHEMBL15688315 | 0.79 | MGAM (0.58) | — | |
| SCHEMBL28787764 | 0.79 | TSHR (0.65) | — | |
| SCHEMBL28015820 | 0.79 | TSHR (0.50) | — | |
| SCHEMBL1568475 | 0.77 | GAA (0.64) | — | |
| SCHEMBL7429574 | 0.77 | FAAH (0.38) | — | |
| SCHEMBL11756126 | 0.77 | TSHR (0.61) | — | |
| SCHEMBL7439401 | 0.75 | LMNA (0.41) | — | |
| SCHEMBL9381186 | 0.75 | DGAT1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912467-B1 | ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE | RHODIA CHIMIE SA (FR) | 2002-04-24 | — | — | EP | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20250304594-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS Cav1,2 ACTIVATORS | NOVARTIS AG (CH) | 2025-10-02 | — | — | US | disclosed |
| US-12365690-B2 | Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Cav1.2 activators | NOVARTIS AG (CH) | 2025-07-22 | — | — | US | disclosed |
| CN-115836076-B | Compounds as CAV1.2 activators | 诺华股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250051345-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2025-02-13 | — | — | US | disclosed |
| US-20250002499-A1 | Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4448533-A1 | <SUP2/>? <SUB2/>?V?PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CA1.2 ACTIVATORS | Novartis AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118510782-A | As CaV1.2 Pyridine-3-carboxylic acid ester Compounds of activators | 诺华股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11919911-B2 | Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators | NOVARTIS AG (CH) | 2024-03-05 | — | — | US | disclosed |
| US-4933482-A | HYDROGENATION OF BETA-KETO ACID IN PRESENCE OF RUTHENIUM PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0295109-A1 | Process for preparing optically active alcohol | Takasago International Corporation (JP) | 1988-12-14 | — | — | EP | disclosed |
| US-4686217-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS | FISONS PLC (GB) | 1987-08-11 | — | — | US | disclosed |
| EP-0225175-A2 | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof | FISONS plc (GB) | 1987-06-10 | — | — | EP | disclosed |
| US-4607041-A | CARDIOTONIC AGENTS | FISONS PLC (GB) | 1986-08-19 | — | — | US | disclosed |
| CN-85106878-A | The method for preparing compound | — | 1986-07-23 | — | — | CN | disclosed |
| EP-0174131-A2 | Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
| EP-0174071-A2 | Dihydropyridine derivatives and their production, formulation and use as pharmaceuticals | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
| EP-0169009-A2 | Novel dihydropyridine derivatives and their production, formulation and use as pharmaceuticals | FISONS plc (GB) | 1986-01-22 | — | — | EP | disclosed |
| EP-0125803-A2 | Pharmaceutically active dihydropyridines | FISONS plc (GB) | 1984-11-21 | — | — | EP | disclosed |